HCWB
HCW Biologics Inc

2,856
Mkt Cap
$4.25M
Volume
1.16M
52W High
$17.80
52W Low
$0.4717
PE Ratio
-0.05
HCWB Fundamentals
Price
$0.7385
Prev Close
$0.7525
Open
$0.7258
50D MA
$0.9011
Beta
0.40
Avg. Volume
149,536.63
EPS (Annual)
-$30.96
P/B
-0.92
Rev/Employee
$71,299.78
$26.32
Loading...
Loading...
News
all
press releases
HCW Biologics Secures $7M Licensing Deal for Promising Immunotherapy
HCW Biologics (NASDAQ:HCWB) finalized an exclusive worldwide licensing agreement for its fusion immunotherapeutic candidate HCW11-006, marking a meaningful step in expanding its global development strategy.
24-7 Market News·5d ago
News Placeholder
More News
News Placeholder
Small Cap Stocks To Keep An Eye On - March 16th
CytomX Therapeutics, HCW Biologics, Direxion Daily MU Bull 2X Shares, Meiwu Technology, and AltC Acquisition are the five Small Cap stocks to watch today, according to MarketBeat's stock screener...
MarketBeat·6d ago
News Placeholder
Promising Pharmaceutical Stocks To Keep An Eye On - March 16th
Eli Lilly and Company, CytomX Therapeutics, Pfizer, HCW Biologics, and AbbVie are the five Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks...
MarketBeat·6d ago
News Placeholder
Biotech Breakthroughs and Capital Moves Drive a Busy Market Week
A wave of biotech developments, strategic financings, and emerging-technology announcements shaped market narratives this week, highlighting how innovation across biopharma, AI-driven automation, energy technology, and crypto finance continues to drive investor attention. $CTMX, $NVDA, $HCWB, $KBLB, $CYN, $BMNR, $CLIK, $CIIT, $AIRS, $DFLI
24-7 Market News·6d ago
News Placeholder
HCWB Stock Soars Pre-Market On Positive Research Results For CAR-T Cell Therapy
HCW Biologics said its proprietary multi-cytokine fusion protein reagent, HCW9206, offers a cost-effective way to generate higher-function CAR-T cells for immunotherapy.
Stocktwits·6d ago
News Placeholder
Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7R, and Others DelveInsight
Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7R, and Others | DelveInsight Alopecia Areata Market Set to...
PR Newswire·1mo ago
News Placeholder
HCW Biologics Stock Scores Biggest Gain Since May As Cancer Drug Breakthrough Fuels Blockbuster Hopes
The biotech firm said its next-generation version of Keytruda showed stronger results in early studies and could eventually expand into both cancer and age-related disease treatments.
Stocktwits·7mo ago
<
...
1
>

Latest HCWB News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.